The FDA has announced its plan for systematically reviewing food additives already commercially available for the first time.

AI can determine eczema severity from images, with results correlating with severity assigned by board-certified clinicians.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

A new COVID-19 variant, NB.1.8.1, has spread in the Mediterranean, Southeast Asia, and Western Pacific regions.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

Training for those who administer cosmetic injections is lacking, despite significant growth in demand for fillers in the aesthetic medicine industry.

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

Most clinicians see adolescents with substance use disorders monthly, while about half report screening for them at every visit.

Anti-OX40 medications have been associated with positive efficacy and safety outcomes for the treatment of atopic dermatitis.

Patients with varicose veins have a higher risk for all-cause dementia, while treatment of varicose veins is tied to a lower risk for vascular dementia.

A radionuclide treatment for non-melanoma skin cancer is well tolerated and effective for patients with shallow skin lesions, according to researchers.